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ABSTRACT– Background: Surgical strategy to increase the number of liver transplants in the 
pediatric population is the ex-situ liver transection (reduction or split). However, it is associated 
with complications such as hemorrhage and leaks. The human fibrinogen and thrombin sponge 
is useful for improving hemostasis in liver surgery. Aim: Compare pediatric liver transplants 
with ex-situ liver transection (reduction or split) with or without the human fibrinogen and 
thrombin sponge. Methods: Was performed a prospective analysis of 21 patients submitted 
to liver transplantation with ex-situ liver transection with the application of the human 
fibrinogen and thrombin sponge in the wound area (group A) and retrospective analysis of 59 
patients without the sponge (group B). Results: The characteristics of recipients and donors 
were similar. There were fewer reoperations due to bleeding in the wound area in group A 
(14.2%) compared to group B (41.7%, p=0.029). There was no difference in relation to the 
biliary leak (group A: 17.6%, group B: 5.1%, p=0.14). Conclusion: There was a lower number 
of reoperations due to bleeding of the wound area of  the hepatic graft when the human 
fibrinogen and thrombin sponge were used. 
RESUMO – Racional: Estratégia cirúrgica para aumentar o número de transplantes hepáticos 
na população pediátrica é a transecção hepática ex-situ (redução ou split). No entanto, ela 
está associada com complicações, tais como hemorragia e fístulas. A esponja de fibrinogênio 
e trombina humana é útil para melhorar a hemostasia nas operações hepáticas. Objetivo: 
Comparar transplantes hepáticos pediátricos com transecção hepática ex-situ (redução ou 
split) com ou sem a esponja de fibrinogênio e trombina humana. Métodos: Foi realizada análise 
prospectiva de 21 pacientes submetidos ao transplante de fígado com transecção hepática ex-
situ com a aplicação da esponja de fibrinogênio e trombina humana na área cruenta (grupo A) 
e análise retrospectiva de 59 pacientes sem a esponja (grupo B). Resultados: As características 
dos receptores e doadores eram semelhantes. Observou-se menor número de reoperações 
devido à hemorragia na área da cruenta no grupo A (14,2%) em comparação com o grupo B 
(41,7%, p=0,029). Não houve diferença em relação à fístula biliar (grupo A: 17,6%, grupo B: 5,1%, 
p=0,14). Conclusão: Houve menor número de reoperações por sangramento da área cruenta do 
enxerto hepático quando a esponja de fibrinogênio e trombina humana foi utilizada.
Correspondence: 
Fernando Pompeu Piza Vicentine
Email: fernandoppv@yahoo.com.br
Financial source: Fundo Nacional de Saúde – 
Sistema Nacional de Transplante (SNT)
Conflicts of interest: none
Received for publication: 09/06/2016
Accepted for publication: 30/08/2016
DESCRITORES -  Transplante de fígado, 
Hemostasia. Hepatectomia, Técnicas.
ABCDDV/1250
INTRODUCTION
Pediatric liver transplantation needs to deal with the difficulty of finding small deceased donors in whom the hepatic graft fits the size of the recipient7,20,24 and organ shortage is a problem described by liver transplant teams, making 
the mortality in the awaiting list a reality.
As alternatives to small recipient cases - in an attempt to increase the supply of liver 
grafts - techniques were developed, such as liver transplantation with ex-situ liver transection 
of the graft from the deceased donor. When talking about liver transplantation with ex-
situ liver transection, these are two possible procedures: hepatic reduction or split17,26,30.
Hepatic reduction, described by Bismuth et al. in 19844, a non ruler hepatectomy 
is performed in the hepatic graft (where the hepatic resection line does not preserve the 
hepatic anatomical segments33) during the preparation of the organ at the auxiliary table, 
in order to reduce the size of the graft to fit the size of the recipient.
The split technique was described by Pichlmayr in 198827, in which, from a cadaveric 
donor the liver graft is divided, into an auxiliary table, respecting the anatomic liver 
segments33 and preserving the vascular structures, obtaining two partial grafts able to 
transplant for two different recipients (Figure 1). A graft composed of segments II and III 
(used in a pediatric receptor) and another by segments I, IV-VIII (used in an adult recipient).
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FIGURE 1 - Hepatic graft submitted to split with formation of 
two functional liver grafts: A) graft for the adult; 
B) graft for the child
Currently, the ex-situ liver transection technique achieves 
good results in the literature, with survival rates similar to the 
results of transplants with whole graft13,20,23,24,30, but its use is 
not free of complications such as increased bleeding of the 
wound area of the graft, with greater use of blood products 
and biliary leak14,23,30,36.
The human fibrinogen and thrombin sponge (Tachosil®)16 
is a material to aid in surgical hemostasis, consisting of a matrix 
of collagen associated with a layer of plasma components such as 
coagulation factors, fibrinogen and fibrin. Its use in liver surgery 
was described in studies, showing that after hepatectomy its 
use obtained fast and effective hemostasis in the wound area 
when compared to other methods5,12,14,29. New articles describe 
the use of sponge in the field of liver transplantation with good 
results in relation to hemostasis and biliary leak21,36.
The objective of this study was to compare pediatric 
liver transplantation with the ex-situ liver transection with or 
without the use of the human fibrinogen and thrombin sponge.
METHODS
The project was approved by the Research Ethics Committee 
of the Federal University of São Paulo/Hospital São Paulo, with 
number 38311/2012.
A prospective study of pediatric patients submitted to liver 
transplantation with the ex-situ liver transection technique and 
with the use of the human fibrinogen and thrombin sponge was 
carried out at Hospital São Paulo, Escola Paulista de Medicina 
- UNIFESP, São Paulo, SP, Brazil, from January 2012 to May 
2016. The control group was formed by a historical cohort, 
with prospective data collection, starting in January 2004, of 
all patients submitted to liver transplantation with ex-situ liver 
transection technique without the use of the human fibrinogen 
and thrombin sponge in this same service.
The study included 80 patients and divided into two 
groups: the first, classified as group A, was composed of 21 
patients submitted to the transplantation with the use of the 
human fibrinogen and thrombin sponge; and in the control 
group (group B) were included 59 patients submitted to the 
transplantation without the use of fibrinogen sponge and 
human thrombin.
Inclusion criteria were children of up to 18 years of age, 
of both genders, submitted to liver transplantation with ex-
situ liver transection technique independent of indications of 
liver transplantation. Patients older than 18 years and cases in 
which the parents or guardians refused to sign the free and 
informed consent form were excluded.
Potential donors were selected for hepatic transplantation 
with the ex-situ liver transection technique when, if possible, 
they fit within the criteria of this institution: under 50 years of 
age, hemodynamic stability, less than four days in the intensive 
care, ALAT (U/l) and ASAT (U/l) levels less than twice normal, 
GGT below 50 IU/l, sodium levels below 160 mmol/l and less 
than 30% fat infiltration In the macroscopic analysis. Due to 
the severity of the recipients and the urgency of a liver graft 
for transplantation, not all donors met these criteria.
Aiming for the most appropriate matching between donor 
and recipient, the size, weight and BMI data of both were taken 
into account in the decision to perform the liver transection. 
The logistics between liver graft extraction, liver transection 
(reduction or split) on an auxiliary table, and graft implantation 
were designed to achieve maximum cold ischemia time of 12 h.
After liver graft revascularization, primary hemostasis 
and raffia of the bile ducts of the wound area were performed. 
According to the manufacturer’s instructions, the previously 
moistened sponge and was applied the yellow side, on which 
the active principles of the product were found, to the wound 
surface of the liver graft. Sponge compression was carried 
out with the aid of a wet compress for about 2 min in order to 
obtain a correct sponge fixation and local hemostasis.
When necessary, because of the extent of the wound area 
being larger than the surface of the sponge, more than one 
was used and the application process was repeated (Figure 2).
FIGURE 2 - Liver graft submitted to split using human fibrinogen 
and thrombin sponge in wound area
The outcomes evaluated in this study were: use of blood 
products, bleeding of the wound area, biliary leak and collection 
of the wound area, and survival of the patient and liver graft 
in 30 days.
Statistical analysis
The analyzed data are represented in mean, median, 
standard deviation and percentage. Student’s t-test, chi-square, 
Fisher exact, Mann-Whitney and Kaplan Meier survival curve 
were applied when indicated. The statistical analysis program 
SPSS version 2.0 was used, with p <0.05 being considered 
significant.
RESULTS
The two groups were similar in terms of demographic 
characteristics, including age, gender, diagnosis of liver disease, 
weight, height, blood typing and PELD range.
In relation to the donors, except for the level of bilirubin 
(mg/dl), which was higher in group A (0.71±0.55) than in group 
B (0.47±0.37), but both above the normality, there was no 
difference in the other characteristics and both group were 
similar to age (years), gender, body mass index (BMI), use of 
inhaled drugs, alcohol consumption (mg/dl), creatinine (mg/dl), 
urea (mg/dl), ALAT (U/l), ASAT (U/l), bilirubin (mg/dl), alkaline 
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fibrinogen and thrombin sponge were applied - the reoperation 
rate was lower (14.2%) than in the Group B (41.7%, p=0.029), 
demonstrating that this instrument may help in the hemostasis 
of the wound area of  patients submitted to pediatric liver 
transplantation with the ex-situ liver transection technique 
(reduction or split).
In the literature, articles involving the use of this sponge 
for hemostasis of the wound area in hepatectomy and in liver 
transplants with the ex-situ liver transection technique and/or 
living donor, corroborate this finding5,12,14,21,25,29,36.
In 2008 a traditional pediatric transplant group in Belgium 
published a report of the use of human fibrinogen and thrombin 
sponge in four children undergoing liver transplantation using 
the liver transection technique (two received the left segment 
of alive donor and two a reduced hepatic graft). However, it 
was a series of cases without a control group and the author’s 
opinion is that the human fibrinogen and thrombin sponge 
used on the wound area of  the graft leads to a good and 
effective hemostasis, which occurs by describing the use of 
only one concentrate of red blood cells per patient during 
the transplantation, as no patient presented bleeding in the 
postoperative period21.
In 2011 Mirza et al. published a prospective and multicenter 
study analyzing the use of the human fibrinogen and thrombin 
sponge in a population composed of individuals submitted to 
liver transplantation with the ex-situ liver transection technique 
and others to hepatectomy. Sixteen patients were included, 
13 of whom underwent liver transplantation. The authors 
demonstrated good hemostasis of the wound area with the use 
of the human fibrinogen and thrombin sponge within 3 min 
in 81% of the patients studied25. An interesting point was the 
way of conducting the study, since the population planned for 
the analysis was 40 patients. However, during the study, it was 
interrupted due to the fact that, as the authors wrote, it was 
evident that the data collected were related to the underlying 
liver disease or to the surgical procedure, and not to the use 
of the human fibrinogen and thrombin sponge25.
In this study, there was no statistically significant difference 
in the biliary leak rate of the wound area, as well as in the 
collection area near the wound area between the group that 
used the sponge (5.88% and 14.28%, respectively), and the group 
that did not used the sponge (5.12% and 9.75%, respectively, 
p=0.87 and p=0.68, respectively).
Biliary leak in hepatic transplantation is an important cause 
of morbidity. Literature rates vary from 5-10% of liver transplants 
with whole liver and are directly related to complications of the 
hepatic artery9,16,22,31. In cases of liver transplantation with the 
ex-situ liver transection technique (reduction or split), these 
rates may increase9,10 to 18.8%, as described by Diamond et 
al. in the year 20078.
In the literature, the use of human fibrinogen and thrombin 
sponge and its relation with biliary leak and collection of the 
wound area is still controversial.
Toti et al., in a retrospective study in 2010 demonstrated 
a reduction in the biliary leak rate in adult patients submitted 
to liver transplantation with split and sponge use in the wound 
area compared to fibrin glue use in the wound area, reducing 
the rate of leak of 43.75% without the use of the sponge, to 
6.25% with its use36.
On the other hand, Mirza et al. demonstrate a rate of 
12.5%  of reoperation due to bile leak of the wound area in 
pediatric patients submitted to liver transplantation even with 
the use of the human fibrinogen and thrombin sponge in the 
wound area25.
It was studied the early survival in 30 days, because 
after this period the human fibrinogen and thrombin sponge 
has been absorbed and is no longer present in the patients’ 
bodies. Both groups presented 30-day mortality and graft loss 
in 30 days similar, with no statistically significant difference. 
Patient survival at 30 days in group A was 80.9% and in B, 
phosphatase (U/l) and GGT (U/ l).
Group A consisted of 18 (85.7%) patients submitted to the 
split technique and three (14.3%) to the reduction technique; 
in group B, 36 (61%) patients were submitted to the split 
technique and 23 (39%) to the reduction technique (p=0.056).
The parameters analyzed in the surgical procedure (Table 
1) showed that both groups received red blood cell transfusion, 
and the median use of blood products (ml/kg) was 35.1 in 
group A and 36.5 in group B, without statistically significant 
difference (p=0.83).
TABLE 1 - Liver transplantation data
Group A (n = 21) 
With sponge
Group B (n = 59
Without sponge p
Use of red blood cells 100 % 100 % 1
Hemoderivative (ml/kg) 35,1 36,5 0,83
Reoperation due to bleeding 
of the wound area 14,2% 41,7% 0,029
Collections 14,28% 9,75% 0,68
Bile leak of the wound area 5,88% 5,12% 0,87
When the reoperations by bleeding of the wound area were 
analyzed, there was a lower frequency in group A (14.2%) than 
in B (41.7%), with a statistically significant difference (p=0.029).
Regarding the biliary leak and collection of the wound area, 
as well as the type of treatment indicated for the collection, such 
as reoperation, puncture and drainage of the collections, there 
was no statistical difference when comparing the two groups.
Regarding the early survival in 30 days, comparing the two 
groups, group A presented survival of 80.9% in 30 days and the 
B 87.7%, with no statistically significant difference (p=0.328). 
Early 30-day survival of liver grafts was also similar, comparing 
the two groups (group A: 76.1% and group B: 78.4%, p=0.668).
DISCUSSION
The two groups studied did not present statistical differences 
regarding the demographic characteristics of the donors and 
recipients, forming two groups similar and comparable for 
possible outcomes. The techniques of ex-situ liver transection 
were similar in reduction and split.
An alternative to the ex-situ split technique would be the 
use of split in-situ, in which the liver graft is divided with the 
donor still the heart beating. This technique has already been 
described in the literature1,6,11,18,28,35, and it is known that there is 
an increase of about 2 h during the harvesting operation when 
employed10,28, in addition to the need for adequate equipment 
to perform this procedure in the hospital where the capture 
is performed.
These conditions are difficult to find in Brazil due to their 
extension and non-standardization of health services, so this 
technique has been little used in the country. The Pittisburgh 
transplant group published a comparison between in-situ 
and ex-situ split techniques in 2000, showing no difference in 
patient survival and hepatic graft survival28.
Hemotransfusion frequency was observed in 100% of 
patients in both groups during liver transplantation, red blood 
cell transfusion volume was statistically similar, and the median 
use of blood products (ml/kg) was 35.1 in group A and 36.5 
in group B, with no statistically significant difference (p=0.83).
In a study published in 2010, Toti el al. compared the use 
of human fibrinogen and thrombin sponge with fibrin glue in the 
wound area of  patients submitted to liver transplantation with 
the ex-situ split technique. The authors described no difference 
in the need for the use of blood transfusion between the two 
groups, but did not demonstrate data of transfusion at work 
and only cited this information during the text36.
When the reoperations by bleeding of wound area were 
analyzed we observed that in group A - where the human 
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87.7% (p=0.32). The graft survival in group A was 76.1% and 
in B, 78.4% (p=0.668). Regarding patient and graft survival in 
30-day period, the values  are similar to those presented by the 
other authors in the literature. The one-year survival of pediatric 
patients undergoing liver transplantation with the ex-situ liver 
and graft transection technique is described in the literature in 
about 73% and 63%26, and may reach 91% and 90% in a highly 
specialized center. A review article on liver transplantation with 
the split technique, published in 2003, presented data from 
authors with rates referring to one-year survival of patients 
and grafts ranging from 76% to 100% and 66% to 100%20.
CONCLUSION
Comparing pediatric liver transplantation with the ex-situ 
liver transection technique (reduction or split) with or without 
the use of the human fibrinogen and thrombin sponge, was 
observed a smaller number of reoperations due to bleeding 
of wound area of the liver graft when the human fibrinogen 
and thrombin sponge were used.
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